Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer

Stage IV Prostate Cancer Clinical Trial

Official title:
R2810-ONC-16XX: A Phase 1 Neoadjuvant Study of Stereotactic Body Radiation Therapy With Systemic REGN2810 and Intraprostatic Ipilimumab, Alone or in Combination, in Patients With Locally Advanced Prostate Cancer Prior to Radical Prostatectomy

Status Withdrawn

Clinical Trial Summary

This phase I trial studies the side effects of anti-PD-1 monoclonal antibody REGN2810 (REGN2810) and/or ipilimumab when given together with stereotactic body radiation therapy before surgery in treating participants with prostate cancer that is growing, spreading, or getting worse, and has spread to other places in the body, or formed a small number of new tumors in one or two other parts of the body. Monoclonal antibodies, such as anti-PD-1 monoclonal antibody REGN2810 and ipilimumab, may interfere with the ability of tumor cells to grow and spread. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Giving anti-PD-1 monoclonal antibody REGN2810 and ipilimumab with stereotactic body radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

Clinical Trial Description

PRIMARY OBJECTIVES:

I. To determine the safety and tolerability for an established effective dose of systemic REGN2810 and intraprostatic ipilimumab with stereotactic body radiation therapy (SBRT) in patients with locally advanced prostate cancer with or without oligometastatic disease.

SECONDARY OBJECTIVES:

I. To determine overall pathologic response rate after radical prostatectomy. II. To determine prostate-specific antigen (PSA) progression free survival in men treated with REGN2810 and intraprostatic ipilimumab with SBRT.

III. To determine radiographic progression free survival in men treated with REGN2810 and intraprostatic ipilimumab with SBRT.

IV. Acute and chronic adverse events (AEs). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03477864
Study type	Interventional
Source	Thomas Jefferson University
Contact
Status	Withdrawn
Phase	Phase 1
Start date	December 24, 2018
Completion date	November 4, 2019

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT02491411` - Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel	N/A
Active, not recruiting	`NCT01685125` - Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer	Phase 2
Completed	`NCT00936975` - Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases	Phase 2
Completed	`NCT00087139` - Ixabepilone in Treating Patients With Metastatic Prostate Cancer	Phase 2
Active, not recruiting	`NCT03511196` - Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer	Early Phase 1
Completed	`NCT01881867` - CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer	Phase 2
Completed	`NCT01385059` - Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer	Phase 2
Terminated	`NCT01866423` - Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer	Phase 2
Active, not recruiting	`NCT02807805` - Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer	Phase 2
Completed	`NCT01468532` - Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer	Phase 1/Phase 2
Completed	`NCT01682941` - Soy Isoflavones in Treating Patients With Recurrent Prostate Cancer or Rising Prostate-Specific Antigen	N/A
Completed	`NCT01026623` - Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer	Phase 1/Phase 2
Terminated	`NCT00536991` - Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer	Phase 1/Phase 2
Completed	`NCT00074022` - GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors	Phase 1/Phase 2
Completed	`NCT03707184` - Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone	Phase 2
Withdrawn	`NCT00003534` - Antineoplaston Therapy in Treating Patients With Refractory Stage IV Prostate Cancer	Phase 2
Recruiting	`NCT04113096` - Dibenzyl Trisulphide (GUINEAHEN WEED) for Stage IV Cancer	Early Phase 1
Active, not recruiting	`NCT03344211` - Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer	Phase 2
Terminated	`NCT02985021` - Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies	Phase 2
Recruiting	`NCT02615223` - Endocrine Therapy With or Without Cryoablation for Stage IV Prostate Cancer	N/A